Related Experiment Videos
Therapeutic concentrations of melphalan do not affect yeast cell phagocytosis by monocytes
L Athlin1, L Domellöf, B Norberg
1Department of Surgery, University Hospital, Umeå, Sweden.
Abstract:
The effect of melphalan on monocyte phagocytosis was assessed by studying the uptake of fluorescent yeast cells by glass-adherent monocytes (a fluorescence-quenching technique). In contrast to several other cytotoxic agents, melphalan did not inhibit monocyte phagocytosis. Although the main immunosuppressive side effect of most cytotoxic drugs appears to be due to bone marrow depression with reduction of leukocyte counts, it is reasonable to assume that lack of interference with the function of mature leukocytes is a favourable feature of an antineoplastic drug.
Insights
Melphalan, an antineoplastic drug, does not inhibit monocyte phagocytosis, unlike other cytotoxic agents. This preserved immune cell function is a favorable characteristic for cancer treatment.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Cytotoxic drugs are commonly used in cancer therapy.
- Many cytotoxic agents cause immunosuppression by reducing leukocyte counts.
- The impact of cytotoxic drugs on mature immune cell function requires further investigation.
Purpose of the Study:
- To assess the effect of melphalan on monocyte phagocytosis.
- To compare melphalan's effect on immune cell function with other cytotoxic agents.
Main Methods:
- Monocyte phagocytosis was evaluated using a fluorescence-quenching technique.
- Uptake of fluorescent yeast cells by glass-adherent monocytes was measured.
Main Results:
- Melphalan did not inhibit monocyte phagocytosis.
- This finding contrasts with the effects of several other cytotoxic agents.
Conclusions:
- Melphalan preserves the phagocytic function of monocytes.
- Lack of interference with mature leukocyte function is a beneficial attribute for an antineoplastic drug.